Magic mushroom compound scanned in depression trial

NCT ID NCT06072898

Recruiting now Knowledge-focused Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether psilocybin, the active ingredient in magic mushrooms, changes brain activity in people with depression. Fifty participants will receive either psilocybin or a placebo and undergo MRI scans to measure blood flow and brain network connections. The goal is to understand how psilocybin affects mood-related brain circuits, not to prove it works as a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could reveal how psilocybin affects mood-related brain circuits, pointing toward new ways to treat depression.
What could go wrong: This is a small, early-phase imaging study focused on brain changes, not on proving psilocybin works as a treatment. The results may not lead to a therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

Sunnybrook Health Sciences Centre
RECRUITING

Toronto, Ontario, M4N3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.